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currently used agents, strategies such as cost-sharing to encourage payers to think 
beyond the price tag, and promoting familiarity with novel agents among regional 
and local payers will help optimize the market access opportunity.
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Objectives: The objective of the analysis was to assess the pricing and reimburse-
ment possibilities, as well as the budget impact, of a new medicine for bladder 
cancer immunotherapy. MethOds: We investigated the number of medicines 
for bladder cancer immunotherapy that were registered and listed in the period 
between March 2011 and March 2014, in Serbia. We also made pharmacoeco-
nomics analysis that would be a part of the Health Insurance Fund submission 
file. Results: According to the European Association of Urology (EAU) Guidelines 
for non-muscle invasive bladder cancer (NMIBC) there are several bladder preser-
vation strategies available: intravesical immunotherapy, intravesical chemother-
apy, device-assisted therapy and combination therapy. In Serbia, there are three 
medicines listed for chemotherapy (doxorubicin, epirubicin and mitomycin) and 
one for intravesical immunotherapy (BCG). BCG has become the standard of care 
for high-grade NMIBC and carcinoma in-situ (CIS) and is superior to intravesical 
chemotherapy in reducing recurrences, in preventing or delaying progression of the 
disease. Radical cystectomy should be considered after BCG treatment failure, when 
BCG is contraindicated or not available. BCG is reimbursed in Serbia (wholesale 
price: 79,18€ ) but due to continuous shortages of registered BCG from May 2012, 
non-registered BCG was also listed (price: not defined). Still there was no import, 
due to worldwide shortages. The absence of the treatment encouraged the Serbian 
Institute of Virology, Vaccines and Sera “Torlak” to develop BCG for immunotherapy. 
As the price proposal for new medicine would be 55,43€ , expenses per patient per 
year would be 498,87€ and total costs for 520 patients would be 259.412,40€ , it is 
projected that total savings would be 111.150,00€ per year. Market share of domestic 
BCG would be 0,29% of total B list (hospital medicines) budget. cOnclusiOns: The 
future aim is to develop, register and list domestic BCG that would provide lower 
costs per patient, high quality, availability and the continuous immunotherapy.
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Objectives: To provide a better understanding of: how changes in the use of an 
oncology medicine can affect its aggregate value; how different HTA systems have 
assessed these value expansions; and whether there is a link between value expan-
sions and use. MethOds: We examine all oncology medicines approved by the 
EMA between 2003 and 2005 – giving a sample of 10 medicines. Our framework sets 
out seven possible value expansions beyond an initial approved indication: differ-
ent cancer type; different disease stage; different treatment line/stage; different 
treatment regimen; orphan designation; patient sub-population; and new route of 
administration. We then assessed how HAS (France), NICE (England and Wales), and 
Aetna (US) have recognised these value expansions. Finally, we analysed IMS data 
(2004-2013) on prices, volumes and sales for the five of the medicines. Results: 
Seven of the 10 medicines in the sample have additional value expansions following 
initial indication. Many are now used for indications that are very different from 
their original indication. Most of the HAS assessments resulted in the drug being 
reimbursed but the rewards to the manufacturers were in many cases relatively low 
because few of the recommended drugs were given low “improvement in medical 
service” (ASMR) levels. The majority of NICE appraisals (63%) resulted in the drug/
indication not being recommended for use in the NHS. Generally, the UK had lower 
prices, volumes and sales than France and the US (with some exceptions). The 
comparisons between France and the US were a little more equivocal. There is a 
mixed picture in terms of the correlation between NICE/HAS recommendations and 
sales in the UK/France. We observe a link between expansions in licensed indica-
tions and changes in sales. cOnclusiOns: Health systems and policy makers need 
to recognise how product life-cycle considerations affect the value of medicines, 
and in particular, oncology medicines.
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Objectives: In December 2011, a threshold value of costs/QALY was introduced 
to Slovak legislation. The aim of this work is to assess its impact on inclusion of 
oncology drugs to the reimbursement system and their availability in clinical 
practice. MethOds: We evaluated the inclusion of oncology drugs to the reim-
bursement system based on data from the website of the Ministry of Health SR. 
We analysed the consumption of drugs based on the National Health Information 
Centre database. We acquired information about registered oncology drugs on the 
EMA website. We determined the level of availability of oncology drugs in clini-
cal practice via a qualitative survey among oncologists. Results: The success 
rate of including new oncology drugs in Slovakia was high in 2000-2011. From the 
62 oncology drugs registered in this period by the EMA, 48 were included to the 
Reimbursement List. Innovative oncology drugs were included relatively quickly 
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Objectives: In recent years (2011-2014) various new oncology therapies were 
launched and evaluated by the different market access authorities. The interna-
tional Prismaccess database includes all evaluations and decisions by the respec-
tive authorities in France, Germany and the UK. MethOds: All decisions for new 
oncology therapies which were evaluated by the authorities in France, Germany 
and UK were systematically searched for. A comparison was executed with a 
focus on reimbursement decision, basis of decision, acceptance of submitted 
clinical endpoints, study designs, comparator, quality of life and indirect treat-
ment comparison (ITC). Results: In total there were 23 new oncology therapies 
being evaluated in the three countries. In France 10 decisions were positive (ASMR 
I-III), further 6 of minor improvement (ASMR IV), 20 were positive in Germany 
(n= 3 ‘significant’; n= 6 ‘considerable’; n= 9 ‘minor’; n= 2 ‘non-quantifiable’ added 
benefit) and 4 were positive in England and 5 in Scotland. In 2 cases, respectively 
the assessment was positive (different magnitude) or negative in all countries. 
26% (n= 6) it was similar in at least three countries. (n= 5 positive decisions; n= 1 
negative decision). In case overall survival was the primary endpoint the likeli-
hood was higher in all countries for a positive decision. Key differences in terms 
of decisions were given in acceptance of ITCs, comparator as standard of care and 
ratings for cost-effectiveness. cOnclusiOns: Using the Prismaccess database the 
analysis shows that there might be key differences in terms of evaluation criteria 
between the three countries analysed. In Germany a key focus is given on the 
appropriate comparator(s) and patient-relevant endpoints. In the UK and Scotland 
cost-effectiveness might trump a positive benefit assessment. In France the key 
drivers are not only the severity of the pathology (for tumours, 25% of SMR are not 
substantial), but also efficacy/adverse events ratio, Effective amount, Comparator 
choice and Therapeutic strategy.
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Objectives: Korean government has been making efforts to improve the access 
of orphan drugs or cancer drugs to patients since it is difficult for these drugs 
to be reimbursed due to its high price or lack of clinical evidence. We aim to 
investigate the current status of reimbursement and reviewed related schemes 
in Korea. MethOds: Appraisal results for orphan or cancer drugs during 7 years 
(2007~2013) were included and recommendation rate, final listing rate and order of 
entry among 8 countries were analyzed. Results:  Total 331 were recommended to 
be reimbursed in overall 467 appraisal results (71%), whereas 74 was recommended 
to be reimbursed among 121 results for orphan or cancer drugs (61%), indicating 
that it was less likely to be recommended for those drugs. Fifty eight orphan or 
cancer drugs (48%) were finally listed through NHIC negotiation process. For cancer 
drugs, recommendation and listing rate seem to increase from 47% to 64% and 32% 
to 48% (2008~2010 vs 2011~2013), respectively. Those drugs have been reimbursed 
in the 4.86th place among 8 countries including Korea on the average. Besides, 15 
drugs considered as rule of rescue in those drugs have been listed for reimburse-
ment. cOnclusiOns: We identified that orphan or cancer drugs has been more 
accessible to patients as time goes. As the benefit enhancement plan for four major 
diseases (2013) and the Risk Sharing scheme (2013) have been implemented, it is 
expected for the coverage for those drugs in Korean National Health Insurance to 
be widened through these schemes.
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Objectives: Health technology assessment (HTA), pricing and reimbursement 
(P&R) processes, and cost-containment strategies in France, Germany, Italy, Spain, 
and the UK, are increasingly stringent. This study explored the resulting impact on 
high-cost oncology brands, and carved out specific market access levers and barri-
ers. MethOds: Across the EU5, 500 medical or hematological oncologists were sur-
veyed regarding their current and expected prescribing patterns, and 30 payers who 
influence reimbursement at national or regional level were interviewed. Results: 
Some 68-83% of surveyed oncologists in France, Italy, Spain, and the UK, and 44% 
in Germany report that the average time taken by their health care authority to 
review newly approved cancer treatments and settle reimbursement terms delays 
availability for prescribing by ≥ 6 months. Thereafter, country-specific prescribing 
restrictions impede uptake; e.g., 18% of German hematologists surveyed report 
that their indicative prescribing budget prevents use of ponatinib in > 20% of their 
chronic myeloid leukemia patients, while 30% of Italian medical oncologists say the 
national oncology drugs register monitoring use of costly agents severely restricts 
prescribing of erlotinib and gefitinib for non-small-cell lung cancer. Interviewed 
payers stress, however, that well-designed pivotal trials considering increasing focus 
on added benefit over direct comparators will help optimize HTA and P&R terms, 
with those in Italy and the UK, especially, advocating cost-sharing schemes to secure 
market entry. Furthermore, demonstrable downstream cost savings, locally targeted 
marketing campaigns, and manufacturer estimates of patient population size to aid 
regional/local budget planning are specified as uptake levers. cOnclusiOns: HTA 
and P&R demands and tightening budgets negatively impact prescribing of costly 
oncology brands in the EU5. However, clear demonstration of robust benefits over 
